Immunotherapy plus low-dose chemo for advanced triple-negative breast cancer
Part of Cancer clinical trials.
This study tests a combination of an immunotherapy drug (PD-L1 inhibitor) with a special low-dose chemotherapy regimen (VEX) plus optional radiation for advanced triple-negative breast cancer. The goal is to see if this approach works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have metastatic triple-negative breast cancer (cancer that has spread to other parts of the body).
- You have had no more than one previous chemotherapy treatment for the metastatic breast cancer.
- You are able to do your daily activities without much help (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
- You have either had treatment with anthracycline or taxane chemotherapy before, or your doctor says you cannot take those drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) given with standard chemotherapy, compared to chemotherapy alone, for people with triple-negative breast cancer that has spread and hasn't been helped by earlier treatments. The goal is to see if adding this immunotherapy can shrink tumors or slow the cancer's growth better than chemotherapy alone.
This trial tests a combination of a PD-L1 inhibitor with a low-dose chemotherapy regimen and either immediate or delayed radiation therapy for people with HER2-negative breast cancer that has spread to the brain. The goal is to see if this approach helps shrink brain tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (PD-L1 antibody) along with a low-dose oral chemotherapy ('metronomic') called VEX for people with advanced triple-negative breast cancer. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
Hear when a new Advanced Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.